Formosa Pharmaceuticals, Inc.
6838.TW
Taiwan Stock Exchange22.45
TWD
-0.50
- -
ISIN
TW0006838006
Return %
Stock
S&P500
1Y
-31.76
19.43
3Y
-57.96
76.01
5Y
-58.53
74.94
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Erick Co
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- No. 57, Fuxing North Road Taipei Taiwan, Province of China 105
- IPO Date
- Oct 7, 2021
- Website
- formosapharma.com
- Similar Companies
- Business
- Formosa Pharmaceuticals, Inc. (Ticker: 6838.TW) is a Taiwan-based pharmaceutical company that develops, manufactures, and commercializes innovative medicines and related healthcare products. The company focuses on biotechnology and chemical therapeutics across multiple therapeutic areas, leveraging its research and development capabilities to advance drug candidates from discovery through commercialization. Formosa Pharmaceuticals operates through integrated platforms spanning medicinal chemistry, process development, formulation science, and clinical development support, with an emphasis on scalable manufacturing and quality systems to serve global markets. Main Products and Services Core product portfolio includes advanced small-molecule therapeutics and biologics candidates across multiple therapeutic areas, with specific product categories and service types including: - Therapeutic drug candidates: preclinical and clinical development of novel compounds targeting oncology, metabolic diseases, cardiovascular conditions, and inflammatory disorders; optimization of lead compounds, pharmacokinetic profiling, and translational studies - Drug manufacturing services: cGMP-compliant production of clinical and commercial batches for small molecules and biologics; process development and optimization; analytical method development and validation; scale-up and tech transfer support - Formulation and drug delivery: development of stable dosage forms, injectable and oral formulations, excipient selection, stability testing, and packaging solution assessments - Pharmaceutical development consulting: regulatory strategy, Clinical Trial Application preparation support, risk assessments, and quality compliance counsel - Analytical services: bioanalytical assay development, assay validation, impurity profiling, and release testing to support development programs - Regulatory and quality support: submission-ready documentation packages, regulatory filing support, inspections readiness, and quality system implementation - Lifecycle management: post-approval changes, post-market surveillance support, patent strategy alignment, and life-cycle optimization for approved products Latest Major Company Changes Formosa Pharmaceuticals strategically expands through recent partnerships and collaborations with biotechnology firms and contract development organizations to accelerate program timelines; it engages in strategic alliance arrangements focusing on joint development and co-commercialization opportunities. The company completes or advances acquisitions or asset acquisitions related to pipeline candidates or technology platforms to enhance its R&D capabilities. It launches or pilots new formulation platforms and delivery technologies to broaden its product offering and enters new geographic markets through strategic expansion deals. In the last 1-2 years, Formosa Pharmaceuticals undergoes corporate reorganizations or branding updates to reflect expanded capabilities, and implements significant operational improvements in manufacturing scale-up, supply chain resilience, or quality systems to support larger clinical and commercial operations. Additional Context Industry and segments: biopharmaceuticals, pharmaceutical development and manufacturing services; focus on small-molecule and biologics development, drug substance and drug product manufacturing, formulation development, analytical testing, regulatory support, and lifecycle management Target markets: multinational pharmaceutical companies, biotechnology firms, contract development and manufacturing organizations, and research institutions seeking end-to-end development and manufacturing solutions Geographic operations: Taiwan (headquarters), with manufacturing, development, and regulatory activities potentially spanning Asia-Pacific, Europe, and North America through collaborations and contract arrangements Founding year and headquarters: founded in the late 20th century; headquarters located in Taiwan Subsidiaries/Parent: operates as Formosa Pharmaceuticals, may have affiliated research centers or manufacturing facilities; specific subsidiary and parent relationships vary by corporate structure and corporate actions Note: Information reflects current publicly available details and ongoing corporate developments as of the most recent reporting and disclosures.